Lindsay L. Somerville

Pulmonary Medicine

501 Sunset Ln
Culpeper, VA 22701

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Social risk factors in patients with cystic fibrosis: impacts on exacerbations, lung function, and BMI.

Social risk factors in patients with cystic fibrosis: impacts on exacerbations, lung function, and BMI.

Journal: Therapeutic advances in respiratory disease

Published: December 03, 2025

Epithelial expression of allergic inflammatory type 2 genes in adults with modulator-refractory cystic fibrosis.

Epithelial expression of allergic inflammatory type 2 genes in adults with modulator-refractory cystic fibrosis.

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

Published: September 05, 2025

Cutaneous Adverse Effects of Elexacaftor-Tezacaftor-Ivacaftor: A Single Center Cohort Study on Acne Severity in Adults With Cystic Fibrosis.

Cutaneous Adverse Effects of Elexacaftor-Tezacaftor-Ivacaftor: A Single Center Cohort Study on Acne Severity in Adults With Cystic Fibrosis.

Journal: Journal of cosmetic dermatology

Published: May 13, 2025

Macrophage peroxisomes guide alveolar regeneration and limit SARS-CoV-2 tissue sequelae.

Macrophage peroxisomes guide alveolar regeneration and limit SARS-CoV-2 tissue sequelae.

Journal: Science (New York, N.Y.)

Published: March 06, 2025

Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population.

Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population.

Journal: Therapeutic advances in respiratory disease

Published: November 15, 2024

Analysis of iron status after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.

Analysis of iron status after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.

Journal: Pediatric pulmonology

Published: August 02, 2023

Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis.

Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis.

Journal: Pharmacotherapy

Published: June 20, 2023

Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19.

Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19.

Journal: Science immunology

Published: February 23, 2023

COVID-19 patients exhibit unique transcriptional signatures indicative of disease severity.

COVID-19 patients exhibit unique transcriptional signatures indicative of disease severity.

Journal: Frontiers in immunology

Published: July 08, 2022

Mental health screening of patients with cystic fibrosis through telehealth during COVID-19: Evaluation of feasibility and process adoption.

Mental health screening of patients with cystic fibrosis through telehealth during COVID-19: Evaluation of feasibility and process adoption.

Journal: Families, systems & health : the journal of collaborative family healthcare

Published: May 23, 2022

Social determinants of health screening and intervention: A cystic fibrosis quality improvement process.

Social determinants of health screening and intervention: A cystic fibrosis quality improvement process.

Journal: Pediatric pulmonology

Published: March 16, 2022

Cystic fibrosis learning network telehealth innovation lab during the COVID-19 pandemic: a success QI story for interdisciplinary care and agenda setting.

Cystic fibrosis learning network telehealth innovation lab during the COVID-19 pandemic: a success QI story for interdisciplinary care and agenda setting.

Journal: BMJ open quality

Published: February 07, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026